Compare INSP & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | WVE |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2015 |
| Metric | INSP | WVE |
|---|---|---|
| Price | $50.53 | $5.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $94.00 | $29.81 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,050,000.00 | $3,704,000.00 |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $8.11 | $85.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 62.18 | ★ 149.43 |
| 52 Week Low | $38.91 | $5.02 |
| 52 Week High | $147.03 | $21.73 |
| Indicator | INSP | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 45.35 |
| Support Level | $48.30 | $5.48 |
| Resistance Level | $58.45 | $6.48 |
| Average True Range (ATR) | 2.28 | 0.32 |
| MACD | 0.58 | 0.03 |
| Stochastic Oscillator | 81.23 | 41.62 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.